Evidence map›Paper›PMID 20102408›Full record

ArticleImmunology2010

Acidification-dependent activation of CD1d-restricted natural killer T cells is intact in cystic fibrosis.

Sarah E Rzemieniak, Aaron F Hirschfeld, Rachel E Victor, Mark A Chilvers, Dongjun Zheng, Peter van den Elzen, Stuart E Turvey

Open access · greenAbstract read
In one paragraph

Article in Immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Frontiers in immunology · 2024
    Review
  2. Article
  3. Low sphingosine-1-phosphate impairs lung dendritic cells in cystic fibrosis.American journal of respiratory cell and molecular biology · 2013
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sarah E RzemieniakDepartment of Pediatrics, BC Children's Hospital and Child & Family Research Institute, University of British Columbia, Vancouver, BC.
Aaron F Hirschfeld
Rachel E Victor
Mark A Chilvers
Dongjun Zheng
Peter van den Elzen
Stuart E Turvey
Child and Family Research Institute · CABC Children's Hospital · CAUniversity of British Columbia · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

CD1d-restricted natural killer T (NKT) cells are emerging as critical regulators of the immune response to infectious agents, including Pseudomonas aeruginosa; and therapies to augment NKT-cell activation may represent a novel approach to treat chronic, antibiotic-resistant bacterial infections. We examined the capacity of dendritic cells (DCs) from people with cystic fibrosis (CF) to activate NKT cells. Our study was motivated by three lines of evidence: (i) NKT cells play a critical role in clearing P. aeruginosa infection; (ii) activation of NKT cells requires acidification-dependent processing of glycolipid antigens within the endolysosomal compartment; and (iii) endolysosomal acidification may be reduced in CF. We demonstrated that NKT-cell activation was dependent upon intact organelle acidification as inhibitors of the vacuolar (H(+))-ATPases prevented DCs from activating NKT cells with two glycolipid antigens, alpha-galactosylceramide and galactose-galactosylceramide. In contrast, cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel dysfunction had no significant biological impact on the capacity of DCs to activate NKT cells. Dendritic cells from subjects with CF and DCs treated with the thiazolidinone CFTR(inh)-172 inhibitor showed no reduction in their ability to activate NKT cells. Based on these data, we find no evidence for an inherent defect in glycolipid antigen presentation to NKT cells in CF subjects.

Indexed as

Antigen PresentationAntigens, BacterialAntigens, CD1dCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDendritic CellsDrug Resistance, BacterialEndosomesFemaleGalactosylceramidesHumansLymphocyte ActivationMaleNatural Killer T-CellsPseudomonas aeruginosaPseudomonas Infectionsalpha-galactosylceramideAntigens, BacterialAntigens, CD1dCD1D protein, humanCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorGalactosylceramidesThiazolidinediones

Identifiers

PMID20102408
PMCPMC2878472
OpenAlexW1556807199

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.